目的 探讨维拉帕米联合氯沙坦钾治疗高血压的临床疗效。方法 选取2018年2月-2019年2月在首都医科大学附属北京天坛医院治疗的高血压患者96例，根据用药的差别分为对照组（48例）和治疗组（48例）。对照组口服氯沙坦钾片，起始剂量50 mg/次，1次/d，必要时可增至100 mg/次，1次/d；治疗组在对照组的基础上口服盐酸维拉帕米片，起始剂量80 mg/次，3次/d，最大剂量360~480 mg/d，对于低剂量即有反应的老年人或体型瘦小者，起始40 mg/次，3次/d。两组患者治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者血压、C反应蛋白（CRP）、可溶性凝集素样氧化低密度脂蛋白受体1（sLOX-1）、可溶性细胞间粘附分子-1（sICAM-1）、基质金属蛋白酶-9（MMP-9）、转化生长因子β1（TGF-β1）、单核细胞趋化蛋白1（MCP-1）和血管内皮功能。结果 治疗后，对照组临床有效率为81.25%，显著低于治疗组的97.92%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者收缩压（SBP）、舒张压（DBP）均显著下降（P<0.05），且治疗组患者血压水平明显低于对照组（P<0.05）。治疗后，两组患者血清CRP、sLOX-1、sICAM-1、MMP-9、TGF-β1、MCP-1水平均明显降低（P<0.05），且治疗组患者这些血清细胞因子水平明显低于对照组患者（P<0.05）。治疗后，两组肱动脉内皮依赖性舒张功能（EDD）、肱动脉非内皮依赖的舒张功能（NMD）均明显升高（P<0.05），且治疗组患者血管内皮功能明显高于对照组（P<0.05）。结论 维拉帕米联合氯沙坦钾治疗高血压可显著降低患者血压，改善患者临床症状和血管内皮功能。

Objective To investigate the clinical efficacy of verapamil combined with losartan potassium in treatment of hypertension. Methods Patients (96 cases) with hypertension in Beijing Tiantan Hospital, Capital Medical University from February 2018 to February 2019 were divided into control (48 cases) and treatment (48 cases) groups based on different treatments. Patients in the control group were po administered with Losartan Potassium Tablets, the initial dose was 50 mg/time, once daily, and increased to 100 mg/time if necessary, once daily. Patients in the treatment group were po administered with Verapamil Hydrochloride Tablets on the basis of the control group, the initial dose was 80 mg/time, three times daily, the maximum dose was 360-480 mg/d, the initial doses for low-dose responders in elderly or thin people was 40 mg/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure, CRP, sLOX-1, sICAM-1, MMP-9, TGF-β1, MCP-1, and vascular endothelial function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 97.92% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the SBP and DBP in two groups were significantly decreased (P<0.05), and the blood pressure level in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the CRP, sLOX-1, sICAM-1, MMP-9, TGF-β1, and MCP-1 in two groups were significantly decreased (P<0.05), and the serum cytokines levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the EDD and NMD value in two groups was significantly increased (P<0.05), and the vascular endothelial function in the treatment group were significantly better than that in the control group (P<0.05). Conclusion Verapamil combined with losartan potassium in treatment of hypertension can significantly reduce blood pressure, improve the clinical symptoms and vascular endothelial function.